These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18259169)

  • 1. Weighing the outcomes.
    Russo MJ; Balekdjian D
    Nat Biotechnol; 2008 Feb; 26(2):173-82. PubMed ID: 18259169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 3. Beware the biotech barker.
    Jacobs T
    Nat Biotechnol; 2005 May; 23(5):538. PubMed ID: 15877065
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 5. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 7. Where the money is.
    Fitzgerald M
    Nat Biotechnol; 2006 Mar; 24(3):240-2. PubMed ID: 16525370
    [No Abstract]   [Full Text] [Related]  

  • 8. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 9. Organic synthesis remains relevant in drug discovery.
    Mehrotra MM
    Nature; 2007 Oct; 449(7162):535. PubMed ID: 17914370
    [No Abstract]   [Full Text] [Related]  

  • 10. A change in the market--investing in diagnostics.
    Batchelder K; Miller P
    Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
    [No Abstract]   [Full Text] [Related]  

  • 11. Industry ponders reimbursement crisis.
    Bouchie A
    Nat Biotechnol; 2003 Apr; 21(4):347-8. PubMed ID: 12665810
    [No Abstract]   [Full Text] [Related]  

  • 12. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 13. What's fueling the biotech engine-2009-2010.
    Aggarwal S
    Nat Biotechnol; 2010 Nov; 28(11):1165-71. PubMed ID: 21057482
    [No Abstract]   [Full Text] [Related]  

  • 14. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 16. The procedure for marketing authorization for veterinary medicinal products derived from biotechnology in the European community.
    Brunko P
    Dev Biol Stand; 1992; 79():11-5. PubMed ID: 1286745
    [No Abstract]   [Full Text] [Related]  

  • 17. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 18. Paying over the odds.
    Jacobs T
    Nat Biotechnol; 2006 Jan; 24(1):29. PubMed ID: 16404388
    [No Abstract]   [Full Text] [Related]  

  • 19. Commercialization of nanotechnology.
    Hobson DW
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(2):189-202. PubMed ID: 20049790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protection racket.
    Jacobs T
    Nat Biotechnol; 2006 Sep; 24(9):1081. PubMed ID: 16964213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.